TalkSooner and Baldwin Community School collaborate on youth vaping education

Sep.02.2022
TalkSooner and Baldwin Community School collaborate on youth vaping education
TalkSooner works with Michigan schools to educate parents and teens about the dangers and risks of electronic cigarette addiction.

As the number of teenagers vaping across the United States continues to rise, many school districts in West Michigan are taking measures to educate families about the dangers of addiction, including the Baldwin Community Schools.


TalkSooner is an organization dedicated to helping parents and teenagers understand the dangers of drug abuse. They are currently working in collaboration with Baldwin School to educate and facilitate discussions on the topic of teen use of electronic cigarettes.


This organization is a cooperative organization between Allegan County, Berrien County, Kent County, Muskegon County, and Ottawa County in western Michigan. It is coordinated by the West Michigan Shoreline Regional Development Commission (now known as the West Michigan Shoreline Regional Entity).


Recently, the organization partnered with the Baldwin Community School to launch a new education tool that will serve those who can provide information on e-cigarette use for teenagers.


This vehicle made its debut in the area on August 24th. The car displays information in English on one side and in Spanish on the other side through TalkSooner.


According to data from the 2018 National Youth Tobacco Survey (NYTS), the use of electronic cigarettes among current middle and high school students increased by 48% between 2017 and 2018. As of 2018, over 3.6 million children are currently using electronic cigarettes.


Griffin stated, "If you look at smoking, we almost didn't see the number of people smoking in the 50s and 60s because we not only had prevention, but education," Griffin said. "We now know smoking brings harm and can change our lives. We hope to ensure that we take the same measures for children who start vaping at 13 or 14 years old, to catch and quit this habit early or at least make them aware of the dangers that come with it.


On June 4, 2019, Governor Gretchen Whitmer signed Senate Bills 106 and 155, prohibiting the sale and possession of electronic cigarettes to anyone under the age of 18. In December of the same year, federal legislation was signed, raising the legal age to purchase or use tobacco products, including e-cigarettes, to 21. Despite these measures, many remain skeptical of the number of young students still using e-cigarettes.


Griffin has seen firsthand how difficult it is for parents to talk to teenagers about using e-cigarettes after her own child used them. "Preventative education seems to be the most important, not just for your physical health, but also for your mental and overall well-being," she said. "Even in the most educated households, there is still susceptibility to the pressures of e-cigarettes and such. I always encourage parents to have open conversations with their children, discussing their own struggles or choices made by young people. I also suggest trying to find out why they are interested in e-cigarettes or the root cause of their decision to use them.


In September 2018, the US Food and Drug Administration (FDA) sent over 1,300 warning letters and civil monetary penalties to retailers illegally selling e-cigarette products to minors, with the majority being blu, JUUL, Logic, MarkTen XL, and Vuse; this marked the FDA's largest coordinated enforcement effort to date.


According to the Centers for Disease Control and Prevention, some e-cigarette products have labels that do not disclose that they contain nicotine, while some e-cigarette liquids marketed as containing 0% nicotine have been found to contain nicotine.


Using nicotine during adolescence can damage the parts of the brain that control attention, learning, emotions, and impulse control, and may also impair brain development in teenagers. This damage can persist into the mid-20s.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not reflect the views of 2FIRSTS and we cannot verify the accuracy or truthfulness of its contents. The compilation of this article is only intended for industry-related research and exchange.


Due to limitations in the level of translation, the translated article may not express exactly the same meaning as the original. Please refer to the original text for accuracy.


2FIRSTS fully aligns its statements and position with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or international issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives